Tesamorelin vs Ipamorelin: Research Comparison | Regena

Tesamorelin is a stabilised 44-amino-acid analogue of native human GHRH with a trans-3-hexenoyl modification at the N-terminus that protects against DPP-4 degradation while preserving the full 44-residue sequence. It acts at the GHRH receptor in the anterior pituitary to drive pulsatile growth-hormone release.

Ipamorelin is a selective pentapeptide agonist at the growth-hormone-secretagogue receptor (ghrelin receptor / GHS-R1a). It is engineered for clean GH-release pharmacology without the cortisol, prolactin or appetite-axis off-targets seen in earlier GHRPs such as GHRP-6 and GHRP-2.

Tesamorelin is selective for the GHRH receptor. The full 44-residue sequence preserves the native receptor-binding geometry and provides a clean GHRH-axis signal in research models — the IGF-1 response in published research follows the natural pulsatile GH release.

Ipamorelin is selective for the ghrelin receptor. The two compounds engage complementary arms of the growth-hormone axis, which is why matched panels of a GHRH analogue paired with a ghrelin agonist are one of the most common growth-hormone secretagogue research designs.

Tesamorelin has a short-to-medium pharmacokinetic half-life — typically reported around 30–40 minutes after subcutaneous research dosing — supporting a once-daily research cadence in published preclinical and translational protocols.

Ipamorelin also has a short pharmacokinetic half-life (roughly two hours in published research) and is typically used in once- or twice-daily research cadences. Both compounds are stable to standard lyophilisation and reconstitution, with similar storage and handling profiles.

Tesamorelin is used in research models of GHRH-axis signalling, hepatic-lipid research (where the extensive HIV-lipodystrophy translational literature is a reference base) and any protocol that needs the full 44-residue GHRH-receptor activation profile.

Ipamorelin is used in selective ghrelin-receptor research, in growth-hormone-axis research that needs a clean GHRP without GHRP-6 / GHRP-2 off-targets, and as the ghrelin-axis arm in combined-axis panels paired with a GHRH analogue.

Both Tesamorelin and Ipamorelin ship from Regena only after independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.

Batch COAs for both compounds are published on the Regena lab reports page so a research-peptide buyer can audit the analytical detail before purchase. The /trust/how-to-read-a-coa reference walks through every field on a modern Regena COA.

Both tesamorelin and ipamorelin ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C only for long-term storage. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a 28-day in-use stability window under refrigeration for both compounds.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both Tesamorelin and Ipamorelin benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Researchers choose tesamorelin when the protocol targets the GHRH receptor specifically — typically hepatic-lipid research, GHRH-axis signalling work, or when leveraging the published clinical literature is part of the project design. Researchers choose ipamorelin when the protocol targets selective ghrelin-receptor signalling without the off-targets seen in earlier GHRPs. Matched panels of tesamorelin (or CJC-1295) paired with ipamorelin remain one of the most common growth-hormone-secretagogue research designs.

For multi-compound comparator studies, the Regena consultations team will reserve matched-batch inventory of both Tesamorelin and Ipamorelin against a project timeline so the experimental panel is sourced under a single analytical specification window.

Both Tesamorelin and Ipamorelin are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on the Regena site exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.